Recently approved recombinant factor VIII (rFVIII) for the replacement treatment in patients with hemophilia A in Italy

Daniela Paola Roggeri, Ezio Zanon, Alessandro Roggeri

DOI: https://doi.org/10.7175/fe.v18i1.1321

Keywords

Hemophilia A, Recombinant factor VIII, Dosage, Number of administration

Full Text:

HTML PDF

References

  • Hemophilia A. Medscape. Available at http://emedicine.medscape.com/article/779322-overview#a4 (last accessed June 2017)
  • Abbonizio F, Giampaolo A, Arcieri R, Hassan HJ e Associazione Italiana Centri Emofilia (AICE). National Register of Congenital Coagulation Disorders. Report 2014. Roma: Istituto Superiore di Sanità; 2016 (Rapporti ISTISAN 16/20)
  • Forsyth AL, Gregory M, Nugent D, et al. Haemophilia Experiences, Results and Opportunities (HERO) study: survey methodology and population demographics. Haemophilia 2014; 20: 44-51; https://doi.org/10.1111/hae.12239
  • Forsyth AL, Witkop M, Lambing A, et al. Associations of quality of life, pain, and self-reported arthritis with age, employment, bleed rate, and utilization of hemophilia treatment center and health care provider services: results in adults with hemophilia in the HERO study. Patient Prefer Adherence 2015; 9: 1549-60; https://doi.org/10.2147/PPA.S87659
  • European Medicines Agency – EMA. Committee for medicinal products for human use – CHMP. Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products. EMA/CHMP/BPWP/144533/2009. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/02/WC500201773.pdf (last accessed June 2017)
  • Rocino A, Coppola A, Franchini M, et al. Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfusion 2014; 12: 575-98; https://doi.org/10.2450/2014.0223-14
  • Strawczynski H, Stachewitsch A, Morgenstern G, et al. Delivery of care to hemophilic children: home care versus hospitalization. Pediatrics 1975; 51: 986-91
  • Garger S, Severs J, Regan L, et al. BAY 81-8973, a full-length recombinant factor VIII: manufacturing processes and product characteristics. Haemophilia 2017; 23: e67-e78; https://doi.org/10.1111/hae.13148
  • Kavakli K, Yang R, Rusen L, et al.; LEOPOLD II Study Investigators. Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). J Thromb Haemost 2015; 13: 360-9
  • Saxena K, Lalezari S, Oldenburg J, et al. Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial. Haemophilia 2016; 22: 706-12; https://doi.org/10.1111/hae.12952
  • Ljung R, Kenet G, Mancuso ME, et al. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe hemophilia A: results of the LEOPOLD Kids Trial. Haemophilia 2016; 22: 354-60; https://doi.org/10.1111/hae.12866
  • Elocta®– Summary of Product characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003964/WC500198642.pdf (last accessed June 2017)
  • Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood 2012; 119: 3031-7
  • Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123: 317-25; https://doi.org/10.1182/blood-2013-10-529974
  • Afstyla® – Summary of Product characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004075/WC500224591.pdf (last accessed June 2017)
  • Stasyshyn O, Djambas Khayat C, Iosava G, et al. Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial. J Thromb Haemost 2017; 15: 636-44; https://doi.org/10.1111/jth.13647
  • Mahlangu J, Kuliczkowski K, Karim FA, et al. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. Blood 2016; 128: 630-7; https://doi.org/10.1182/blood-2016-01-687434
  • Advate® – Summary of Product characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000520/WC500022467.pdf (last accessed June 2017)
  • Helixate NexGen® – Summary of Product characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000276/WC500047822.pdf (last accessed June 2017)
  • Refacto AF® – Summary of Product characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000232/WC500049008.pdf (last accessed June 2017)
  • Kogenate Bayer® – Summary of Product characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000275/WC500044445.pdf (last accessed June 2017)
  • Recombinate® – Summary of Product characteristics. Available at https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_003822_028687_RCP.pdf&retry=0&sys=m0b1l3
  • Nuwiq® – Summary of Product characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002813/WC500179340.pdf (last accessed June 2017)
  • Kovaltry®– Summary of Product characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003825/WC500202781.pdf (last accessed June 2017)
  • NovoEight® – Summary of Product characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002719/WC500157553.pdf (last accessed June 2017)
  • Regione Calabria. Tabelle relative al 28° aggiornamento elenco unico dei farmaci del PHT di cui agli Accordi Quadro stipulati tra la Regione Calabria e le Industrie Farmaceutiche per l’acquisto dei farmaci del PHT di cui alla Determinazione AIFA del 29 ottobre 2004 e s.m.i. Available at http://www.regione.calabria.it/sanita/allegati/novit/28_aggiornamento_dellelenco_dei_farmaci_in_accordo_quadro.pdf (last accessed June 2017)
  • Regione Autonoma della Sardegna. AO “G. Brotzu”, Cagliari. Deliberazione n.562 del 15/03/2017. Available at http://www.aobrotzu.it/documenti/9_204_20170316092953.pdf (last accessed June 2017)
  • Regione Autonoma della Sardegna. AOU di Sassari. Deliberazione n.192 del 12/04/2017. Available at http://www.aousassari.it/documenti/11_175_20170412175041.pdf (last accessed June 2017)
  • Regione Autonoma della Sardegna. AOU di Sassari. Deliberazione n.133 del 08/03/2017. Available at http://www.aousassari.it/documenti/11_175_20170308192010.pdf (last accessed June 2017)
  • Regione Liguria. Asl 3 “Genovese”. Determinazione n.152 del 31/01/2017. Available at http://delibere.asl3.liguria.it/pdf/determinazioni/2017/2017_152_2_77_Pubblico.pdf (last accessed June 2017)
  • Usl Umbria 1. Delibera Del Direttore Generale n. 296 del 08/03/2017
  • Regione del Veneto. AO di Padova. Delibera del Direttore Generale n.410 del 24/03/2017
  • Regione Liguria. Usl 3 “Genovese”. Recepimento gara CRA Liguria 2016 prodotti farmaceutici per un periodo di mesi 24, con opzione di rinnovo per ulteriori mesi 12 lotto 352 A – Refacto Fusengo – Ditta Pfizer
  • Regione Ligura. Usl n.1 Imperiese. Recepimento gara a.li.sa./C.R.A. per la fornitura di “prodotti farmaceutici 2016” per mesi 24 + 12 di rinnovo. Ditta Baxalta Italy – lotto 2285 - Advate 1000 UI
  • AUSL della Romagna. Determinazione n. 1396 del 26/05/2017. Autorizzazione alla fornitura di nuovi farmaci per emofilia non aggiudicate nelle procedure intercent-er - periodo dal 30.05.2017 al 31.01.2018
  • Regione Liguria. Usl 3 “Genovese”. Gara 34977564. Farmaco elocta (efmoroctocog fattore VIII della coagulazione) polvere e solvente per soluzione iniettabile uso endovenoso
  • Regione del Veneto. AO di Padova. Delibera del Direttore Generale n. 472 del 06/04/2017
  • Regione del Veneto. Ulss6 Euganea. Deliberazione del Direttore Generale n.164 del 28/03/2017

Refbacks

  • There are currently no refbacks.




© SEEd srl